U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Telaprevir response

MedGen UID:
450486
•Concept ID:
CN078014
•
Sign or Symptom
Synonym: Incivek response
Drug:
Telaprevir
MedGen UID:
406297
•Concept ID:
C1876229
•
Amino Acid, Peptide, or Protein
An orally available peptidomimetic small molecule with activity against hepatitis C virus (HCV). Telaprivir is a selective protease inhibitor that targets the viral HCV NS3-4A serine protease and disrupts processing of viral proteins and formation of a viral replication complex. [from NCI]
Telaprevir
 
Gene (location): IFNL3 (19q13.2)

Definition

PEG-interferon alpha (PEG-IFN 2a and 2b, or PEG-IFN alpha), in combination with ribavirin, is used to treat Hepatitis C Virus (HCV) infection. IFNL3 (also known as IL28B) is a member of the type 3 IFN-alpha family, which are induced by viruses and inhibit HCV replication in vitro. Genetic variants in IFNL3 are associated with increased response (higher sustained virological response rate) to PEG-interferon alpha/ribavirin combination therapy and clearance of HCV. In 2011, the protease inhibitors boceprevir and telaprevir were approved to treat HCV genotype 1 infection in many countries, including the United States and those in the European Union, and are now included in HCV combination therapy. IFNL3 genotype predicts response to this combination therapy and also predicts eligibility for shorter duration of therapy. Guidelines regarding the clinical use of PEG-interferon alpha containing regimens based on IFNL3 genotype have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and are available on the PharmGKB website. [from Clinical Pharmacogenetics Implementation Consortium]

Professional guidelines

PubMed

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.
Cammà C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, Cicchetti A, Colombo GL, Di Marco V, Gasbarrini A, Craxì A; WEF Study Group
Hepatology 2012 Sep;56(3):850-60. Epub 2012 Jul 12 doi: 10.1002/hep.25734. PMID: 22454336

Recent clinical studies

Etiology

Synthesis and structure-activity relationship study of new biaryl amide derivatives and their inhibitory effects against hepatitis C virus.
Liu Y, Li J, Gu Y, Ma L, Cen S, Peng Z, Hu L
Eur J Med Chem 2022 Jan 15;228:114033. Epub 2021 Dec 1 doi: 10.1016/j.ejmech.2021.114033. PMID: 34883293Free PMC Article
High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.
Schulkind J, Stephens B, Ahmad F, Johnston L, Hutchinson S, Thain D, Ward Z, Vickerman P, Hickman M, Dillon JF
J Viral Hepat 2019 May;26(5):519-528. Epub 2018 Dec 12 doi: 10.1111/jvh.13035. PMID: 30422370
New approaches in the treatment of hepatitis C.
González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J
World J Gastroenterol 2016 Jan 28;22(4):1421-32. doi: 10.3748/wjg.v22.i4.1421. PMID: 26819511Free PMC Article
Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care.
Muir AJ
Top Antivir Med 2014 Sep-Oct;22(4):685-9. PMID: 25398070Free PMC Article
Hepatitis C therapy update.
Casey LC, Lee WM
Curr Opin Gastroenterol 2012 May;28(3):188-92. doi: 10.1097/MOG.0b013e3283528e1e. PMID: 22476156

Diagnosis

New approaches in the treatment of hepatitis C.
González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J
World J Gastroenterol 2016 Jan 28;22(4):1421-32. doi: 10.3748/wjg.v22.i4.1421. PMID: 26819511Free PMC Article
Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S
J Hepatol 2014 Mar;60(3):530-7. Epub 2013 Nov 19 doi: 10.1016/j.jhep.2013.11.009. PMID: 24269472
Novel therapeutic approaches for hepatitis C.
Au JS, Pockros PJ
Clin Pharmacol Ther 2014 Jan;95(1):78-88. Epub 2013 Oct 14 doi: 10.1038/clpt.2013.206. PMID: 24126682
Interferon free therapy with direct acting antivirals for HCV.
Asselah T, Marcellin P
Liver Int 2013 Feb;33 Suppl 1:93-104. doi: 10.1111/liv.12076. PMID: 23286852
Treatment failure with new hepatitis C drugs.
Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P
Expert Opin Pharmacother 2012 Feb;13(3):313-23. Epub 2012 Jan 14 doi: 10.1517/14656566.2012.653341. PMID: 22242928

Therapy

A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.
Broglio KR, Daar ES, Quintana M, Yuan Y, Kalsekar A, Spellberg B, Lewis RJ, Akker Dv, Detry MA, Le T, Berry SM
J Comp Eff Res 2015 Mar;4(2):101-14. doi: 10.2217/cer.14.69. PMID: 25825840
Interferon free therapy with direct acting antivirals for HCV.
Asselah T, Marcellin P
Liver Int 2013 Feb;33 Suppl 1:93-104. doi: 10.1111/liv.12076. PMID: 23286852
Immunology of hepatitis C virus infections.
Spaan M, Janssen HL, Boonstra A
Best Pract Res Clin Gastroenterol 2012 Aug;26(4):391-400. doi: 10.1016/j.bpg.2012.09.005. PMID: 23199499
Drug therapy: telaprevir.
Leise MD, Kim WR, Canterbury KM, Poterucha JJ
Hepatology 2011 Oct;54(4):1463-9. doi: 10.1002/hep.24660. PMID: 21898509
Telaprevir user's guide.
Liapakis A, Jacobson I
Clin Liver Dis 2011 Aug;15(3):555-71. doi: 10.1016/j.cld.2011.05.013. PMID: 21867936

Prognosis

Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?
Serfaty L
Liver Int 2014 Feb;34 Suppl 1:11-2. doi: 10.1111/liv.12407. PMID: 24373072
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V, Sansonno D, Russi S, Pavone F, Dammacco F
J Infect 2014 Jan;68(1):1-20. Epub 2013 Sep 4 doi: 10.1016/j.jinf.2013.08.019. PMID: 24012819
Drug therapy: telaprevir.
Leise MD, Kim WR, Canterbury KM, Poterucha JJ
Hepatology 2011 Oct;54(4):1463-9. doi: 10.1002/hep.24660. PMID: 21898509
The HIV/HCV-coinfected patient and new treatment options.
Vachon ML, Dieterich DT
Clin Liver Dis 2011 Aug;15(3):585-96. doi: 10.1016/j.cld.2011.05.006. PMID: 21867938
Big changes are coming in hepatitis C.
Poordad F
Curr Gastroenterol Rep 2011 Feb;13(1):72-7. doi: 10.1007/s11894-010-0153-9. PMID: 21063814Free PMC Article

Clinical prediction guides

Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?
Serfaty L
Liver Int 2014 Feb;34 Suppl 1:11-2. doi: 10.1111/liv.12407. PMID: 24373072
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V, Sansonno D, Russi S, Pavone F, Dammacco F
J Infect 2014 Jan;68(1):1-20. Epub 2013 Sep 4 doi: 10.1016/j.jinf.2013.08.019. PMID: 24012819
Genomics and HCV infection: progression of fibrosis and treatment response.
Estrabaud E, Vidaud M, Marcellin P, Asselah T
J Hepatol 2012 Nov;57(5):1110-25. Epub 2012 May 30 doi: 10.1016/j.jhep.2012.05.016. PMID: 22659520
The HIV/HCV-coinfected patient and new treatment options.
Vachon ML, Dieterich DT
Clin Liver Dis 2011 Aug;15(3):585-96. doi: 10.1016/j.cld.2011.05.006. PMID: 21867938
Big changes are coming in hepatitis C.
Poordad F
Curr Gastroenterol Rep 2011 Feb;13(1):72-7. doi: 10.1007/s11894-010-0153-9. PMID: 21063814Free PMC Article

Recent systematic reviews

Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review.
Pecoraro V, Cariani E, Villa E, Trenti T
Eur J Clin Invest 2016 Aug;46(8):737-48. doi: 10.1111/eci.12656. PMID: 27376688
A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
Taieb V, Pacou M, Ho S, Pettré S, Van Sanden S, Pisini M, Ustianowski A, Mehnert A
J Med Econ 2015;18(10):787-96. Epub 2015 May 26 doi: 10.3111/13696998.2015.1046880. PMID: 25934147
Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.
Smith-Palmer J, Cerri K, Valentine W
BMC Infect Dis 2015 Jan 17;15:19. doi: 10.1186/s12879-015-0748-8. PMID: 25596623Free PMC Article
Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis.
Manzano-Robleda Mdel C, Ornelas-Arroyo V, Barrientos-Gutiérrez T, Méndez-Sánchez N, Uribe M, Chávez-Tapia NC
Ann Hepatol 2015 Jan-Feb;14(1):46-57. PMID: 25536641
Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis.
Gu L, Chen Q, Xie J, Yan Y, Wu G, Tan J, Liang B, Chen W, Wu P, Su L, Tang N
Pharmazie 2012 Dec;67(12):963-72. PMID: 23346756

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • Gene
      Related information in NCBI Gene
    • GTR
      Related information in GTR
    • GTR(Clinical)
      Clinical tests in GTR
    • OMIM(Genes)
      OMIM records containing genes associated with phenotypes registered in MedGen
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...